PWP3: CONSUMER PREFERENCES FOR DENTAL ANESTHESIA: PUTTING YOUR MONEY WHERE YOUR MOUTH IS  by Matthews, D et al.
Abstracts 115
OBJECTIVE: The purpose of this investigation was to
compare the experiences of two US corporations, each
employing over 50,000 workers and each offering a com-
prehensive benefit package, in terms of direct (i.e., medi-
cal and pharmaceutical) and indirect (i.e., sick leave and
disability) costs of illness. METHODS: Based on a 1996
sample of workers (n  9439), retrospective medical and
pharmaceutical claims at the employee level were linked
with contemporaneous archival measures of productiv-
ity, including sick leave and disability. These results were
normalized to the age-gender distribution of the US labor
force. To assess the comparability of experiences at each
company, direct and indirect burdens of illness were ex-
amined both in the aggregate as well as at the disease-
group level. RESULTS: The average annual cost of illness
per employee was $3,272 in Company A (59% medical,
9% pharmaceutical, and 32% work loss) and $3,574 in
Company B (44% medical, 9% pharmaceutical, and
47% work loss). Although musculoskeletal diseases rep-
resented the greatest total cost outlay for both companies
(i.e., 10% at Company A, 16% at Company B), the dis-
tribution of direct and indirect costs varied by diagnostic
grouping. CONCLUSIONS: A traditional focus on direct
costs alone would vastly understate the impact of illness
to the employer, since for every dollar of direct expendi-
tures, these companies spent between $0.47 and $0.87 on
additional indirect costs. Worksite and employee health
management programs tailored to the characteristics of
the particular workforce in question could help maximize
return on investment in employee health.
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A METHODOLOGY TO MEASURE 
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Health Outcomes Research (OR) groups exist in most
major pharmaceutical companies and are currently chal-
lenged to quantify their productivity and value to the or-
ganization. Per a recent Tufts survey, industry leaders ex-
pect continued growth in OR departments substantiating
the need for metrics. METHODS: Our OR Department,
positioned within Clinical Research, was approached by
upper management to create a metrics reporting system.
The group discussed a comprehensive list of departmen-
tal activities until core items were agreed upon. Using a
0-10 scale, items were ranked by perceived value to the
company using the Delphi technique. To approximate
time expenditure, complexity categories (1  simple, 2 
moderate, 3  complex), based on estimates of average
number of workdays to complete each activity, were as-
signed to each item. RESULTS: An initial list of 20 items
was reduced by the group to yield 11 core items: publica-
tions (1.8  Delphi weight), models (1.4), strategic plans
(1.3), protocols (0.9), instrument development (0.9), re-
search reports (0.9), abstracts (0.7), reviews (0.6), analy-
sis plans (0.6), presentations (0.5), IPMs (0.4). The value-
score was generated by multiplying the count of each
item by its Delphi-weight then summed to result in a
composite value-score. The complexity-score was calcu-
lated similarly. These two scores, reported separately to
enhance understanding of both output and labor, were
divided by the number of team members to produce pro-
ductivity units per headcount. CONCLUSION: This met-
rics system represents one approach to valuing OR group
contributions. We have implemented a validation and
QA process to observe performance over time and assess
appropriateness of the items selected. This system does
not capture activities conducted to support departmental
and organizational infrastructure. Therefore, is not ap-
propriate for calculating standard costs or for valuing all
contributions attributable to OR groups. In addition to
concisely communicating OR activities to upper-manage-
ment, metrics help team members focus on value-added
activities and project prioritization.
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OBJECTIVES: Consumer preferences and willingness-to-
pay (WTP) were measured for a new dental anesthetic
(dental gel) versus existing anesthetic options for peri-
odontal recall cleanings. METHODS: The study was
conducted by developing and administering a computer-
based interactive survey to study subjects. First, clinical
information was provided, describing periodontal dis-
ease, recall cleaning visits, and anesthetic options (no
freezing, dental needle, and dental gel). Subjects were
asked to choose which freezing option they would prefer,
if they required freezing. Strength of preference for dental
gel was measured using WTP: (1) at the subject’s point of
consumption, and (2) as a monthly dental insurance pre-
mium, for any dental plan beneficiary at the point of con-
sumption. RESULTS: Both recall patients (n  97) and
general population subjects (n  196) participated in the
study. The majority of general subjects (81.0%) and re-
call subjects (82.5%) chose dental gel over other options.
The majority of general subjects (86.7%) and recall sub-
jects (83.8%) who preferred dental gel were willing to
pay for dental gel. The median WTP to have dental gel
available at the point of consumption was $20.00 per
visit for the general population, and $10.00 for the recall
population. The majority of general subjects (72.4%)
and recall subjects (73.2%) were willing to pay an insur-
ance premium for dental gel, even if they did not person-
ally prefer dental gel. The median monthly premium was
$2.00 per month for both groups. CONCLUSIONS:
Dental gel was overwhelmingly preferred by general and
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recall subjects. Most subjects were willing to pay extra to
have dental gel available, both for themselves and for
others, at amounts far exceeding the projected acquisi-
tion price.
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Willingness-to-pay (WTP) provides a method of valuing
diverse outcomes of therapy in monetary units. The
methodology is based on informed individual’s willing-
ness to make trade-offs between health and a wide range
of commodities. OBJECTIVES: To determine the WTP
for weight-loss with two new weight reduction therapies,
orlistat (13.4 lbs) and sibutramine (12–14 lbs) in a Cana-
dian population. METHODS: WTP was assessed in 97
volunteers between the ages of 20 and 64 using contin-
gent valuation. Respondents were randomly assigned to
one of two bid strategies with randomly chosen starting
points. Demographic characteristics (i.e., age, sex, house-
hold income, education, smoking, height, weight, health-
related quality of life (EuroQol), and previous attempts
at weight-loss) were elicited using a standardized ques-
tionnaire. Main effects were tested by ANCOVA control-
ling for age, gender, education, income, smoking, and
obesity (Body Mass Index  30 kg/m2). RESULTS: Re-
spondents had a mean age of 34.6  10.6 years, were
predominantly female (64.6%), and had a mean EuroQol
score of 80.1  15.9 (out of 100). Only 22.7% of the re-
spondents were obese, however 61.9% reported having
tried to lose weight. Respondents stated that they would
be willing to pay an average of 13%  1.3% of their
monthly household income for orlistat and 11.1% 
1.3% for sibutramine (CDN$521 (95% CI: $450–$593)
vs. CDN$446 (95% CI: $375–$518) respectively; F 
0.0805, P  0.371) each month for a period of two years
(CDN$1  US$0.673). Estimates from respondents in
older age groups (P  0.001) and higher income levels (p 
0.001) were significantly associated with higher WTP
values. CONCLUSION: Individuals in Ontario, Canada
place a high value on pharmacologic therapies for weight
reduction.
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Diabetes is known to cause workforce exit after compli-
cations develop, yet little research has examined the ef-
fects of the disease and its treatment on work efficiency
while diabetics are employed. OBJECTIVE: The goal of
this research is to determine whether or not diabetes is
associated with lower levels of work productivity. METH-
ODS: To measure work productivity, a survey was de-
signed to collect data on work efficiency, as defined by
Osterhaus, et al. and van Roijen, et al. The survey also
included items about absences, work history, workforce
exit, job satisfaction, income, demographics and health
care utilization. The survey was administered to diabetic
and non-diabetic people who were employed. RESULTS:
On average, the 72 diabetics who completed the survey
reported significantly lower work productivity than their
362 non-diabetic co-workers. Diabetics averaged the
equivalent of seven hours of lost work time per month
while non-diabetics lost only four hours per month (P 
0.03). Surprisingly, the cost of these productivity losses
was not significantly different between diabetics and
non-diabetics. This is because the diabetics reported in-
comes that averaged $10,000 less per year than their
non-diabetic co-workers (P  0.02). CONCLUSIONS:
Diabetics appear to be less productive at work than their
non-diabetic peers, on average. The cost of lower produc-
tivity appears to be borne, at least in part, by the workers
themselves, who earn significantly less than their non-di-
abetic co-workers, on average. Given the rising preva-
lence of diabetes and variations in treatment patterns, the
effects of diabetes treatments on work productivity and
career progression deserves consideration.
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In Singapore, provision of pharmaceutical care by com-
munity pharmacists is not widely practiced. However,
two patient care centers were established in 1998 by a re-
tail pharmacy chain to provide a range of specialized
pharmaceutical care services. OBJECTIVES: This study
aimed to investigate the feasibility of having such services
in Singapore by (1) characterizing the customers utilizing
the pharmaceutical care services offered to identify a tar-
get group most likely to benefit from such services, and
(2) assessing customers’ perception and acceptance of the
services, as well as their willingness to pay for these ser-
vices. METHODS: A questionnaire was constructed to
evaluate the perception and acceptance of customers uti-
lizing the pharmaceutical care services. The questionnaire
was administered by a face-to-face interview. Qualitative
analysis of the responses was performed and where ap-
propriate, statistical analyses including ANOVA and un-
paired t-test were performed. RESULTS: Seventeen cus-
tomers completed the survey, representing 0.26% of the
